Neupulse Secures Latest Seed Funding Round of £213.3k

Neurotherapeutics Ltd, operating under the brand Neupulse, a Nottingham-based neurotechnology company, has successfully closed a seed funding round, securing £213.3k. The company specialises in developing non-invasive neuromodulation solutions, with its flagship product being a wearable wrist-worn device designed to alleviate tics for individuals living with Tourette Syndrome and other tic disorders.

Incorporated on 12 February 2021, Neupulse addresses a significant need within the neurodiversity community by offering a discreet and accessible treatment option. The company's innovative approach aims to improve the quality of life for those affected by tic disorders through its proprietary technology. While specific revenue or profit/loss figures are not publicly available, the company currently maintains a team of 11 employees, indicating a focused and growing operation dedicated to its mission.

This latest seed round, with an allotment date of 21 April 2026 and a filing date of 30 April 2026, adds to Neupulse's substantial funding history. The £213.3k raise is part of a series of seed investments that have propelled the company's development. Notably, this round follows a larger seed injection of £3m on 6 February 2026 and another significant seed round of £2.5m on 8 February 2024. Other seed funding rounds include £500k on 23 July 2024.

Beyond its formally designated seed rounds, Neupulse has also attracted capital through other funding events. These include £50k on 20 June 2024, £30k on 21 March 2024, and a substantial £917.3k on 14 February 2023, which valued the company at £4.2m. Earlier rounds in 2021 saw the company raise £590k on 6 August 2021 at a £3.2m valuation, and £150k on 5 August 2021 at a £2.7m valuation. This consistent pattern of securing investment underscores investor confidence in Neupulse's technology and its potential market impact.

The company's ability to consistently raise capital, including this recent £213.3k, highlights its trajectory within the UK's health tech and deep tech sectors. The development of electrotherapeutic equipment, particularly non-invasive neuromodulation devices, represents a growing area of innovation. Neupulse's repeated success in securing funding rounds, ranging from smaller strategic investments to multi-million-pound injections, demonstrates a sustained commitment to research, development, and commercialisation within a specialised and impactful segment of the healthcare market. This ongoing financial backing positions Neupulse to continue advancing its technology and expanding its reach to individuals in need of effective tic management solutions.